எய்ட்ஸ் & மருத்துவ ஆராய்ச்சி இதழ்

The emergence of the COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has highlighted the urgent need for effective antiviral therapies and vaccines. In the world of virology, lessons learned from combating other viral infections, such as HIV, can provide valuable insights. One intriguing avenue of research is the potential use of Ezrin Peptide Therapy to inhibit inflammation and expand adaptive antiviral immunity across a range of viral infections, including both HIV and COVID-19.

HIV, the Human Immunodeficiency Virus, remains a global health challenge, affecting millions of people worldwide. While much progress has been made in understanding the virus and developing antiretroviral therapies, there are still many aspects of HIV infection that require further investigation. One such aspect is the impact of HIV on the intestinal mucosa and its role in macromolecule translocation through apoptotic leaks and transcytosis. With the advent of effective antiretroviral therapy, the life expectancy of PLWH has substantially improved. However, this population now faces new challenges, including an increased risk of developing certain types of cancers. This section introduces the topic and highlights the importance of understanding the evolution of cancer incidence in different periods of antiretroviral treatment.

Human Immunodeficiency Virus (HIV) remains a global health challenge, affecting millions of people worldwide. The advent of Highly Active Antiretroviral Therapy (HAART) has transformed HIV infection from a life-threatening disease to a manageable chronic condition, significantly improving the life expectancy and quality of life for individuals living with HIV. Vaccinations play a critical role in safeguarding the health of this vulnerable population, helping to prevent potentially life-threatening infections.

HIV/AIDS remains a global public health challenge, with millions of people worldwide living with the virus. Effective Antiretroviral Therapy (ART) has transformed HIV into a manageable chronic condition, enhancing the quality of life and extending the lifespan of those affected. However, the emergence of drug resistance mutations in the HIV-1 virus poses a significant threat to the success of ART. This article delves into a study conducted in Russia's Northwestern Federal District, focusing on the prevalence and implications of HIV-1 drug resistance mutations among patients experiencing treatment failure. Russia has been grappling with an expanding HIV epidemic for several years. The country has the highest number of new HIV infections in Eastern Europe and Central Asia, with the Northwestern Federal District being one of the regions most severely affected.

In 2015, a cross-sectional study was conducted in Zhejiang, China, to investigate the prevalence of active syphilis infection among HIV-positive men who have sex with men and to identify the associated risk factors. This study sheds light on the intersecting challenges faced by individuals in this vulnerable population and provides valuable insights into the dynamics of Sexually Transmitted Infections (STIs) within the context of HIV in the region. The HIV epidemic in China has been on the rise, particularly among MSM. Simultaneously, the prevalence of syphilis, a bacterial STI, has also been increasing in various parts of the country. Understanding the prevalence and risk factors associated with active syphilis infection in HIV-positive MSM is critical for public health efforts aimed at prevention, diagnosis and treatment.

The quest for an effective HIV vaccine has been ongoing for decades, and despite significant progress in understanding the virus and developing prevention and treatment strategies, a prophylactic vaccine remains elusive. Heterologous prime-boost vaccination strategies, involving the use of different vaccine vectors for initial priming and subsequent boosting, have shown promise in inducing robust and durable immune responses. This article explores the evaluation of a novel approach: using Lumpy Skin Disease Virus (LSDV) as a vector for heterologous prime-boost HIV immunizations. HIV (Human Immunodeficiency Virus) is a complex and highly mutable virus that has defied conventional vaccine development strategies.

The HIV/AIDS epidemic is a global health crisis that affects diverse populations worldwide. In this article, we focus on the specific context of Minnesota, where a significant population of refugees has been affected by HIV/AIDS from 2000 to 2007. We explore the challenges and unique factors influencing the spread and management of HIV/AIDS in this community, examining both medical and social aspects. The analysis draws attention to the need for culturally sensitive healthcare, education, and support programs to address the distinct needs of Minnesota's HIV-infected refugee population.

HIV-1 infection remains a global health challenge, affecting millions of people worldwide. While much progress has been made in managing and treating HIV-1, co-infections and comorbidities continue to pose significant concerns. One such issue is the immune response to Hepatitis B Virus (HBV) vaccination in HIV-1-infected individuals. This article explores the phenomenon of undetectable anti-HBs antibodies in HIV-1-infected individuals and discusses the potential need for booster doses of HBV vaccine to ensure long-term protection. The quest for an effective HIV vaccine has been one of the greatest challenges in modern medicine.

HIV-1 infection remains a global health challenge, with approximately 38 million people living with the virus worldwide. While the advent of highly active Antiretroviral Therapy (HAART) has significantly improved the prognosis and quality of life for individuals living with HIV-1, a complete cure remains elusive due to the persistence of latent HIV-1 reservoirs. HIV-1 latency refers to the ability of the virus to remain dormant in certain cells, evading immune surveillance and antiretroviral drugs. This latent reservoir poses a major barrier to achieving a functional cure for HIV-1. In this review, we delve into the molecular mechanisms underlying HIV-1 latency and discuss current therapeutic approaches aimed at eradicating or controlling this persistent reservoir.